What is 68Ga-PSMA PET studying for renal cell carcinoma?

68Ga-PSMA PET is being studied to see how well it detects metastatic lesions in advanced renal cell carcinoma compared to enhanced CT scans. Researchers want to find out if this imaging technique can improve diagnosis and influence treatment decisions. The study is sponsored by Xijing Hospital and aims to provide better guidance for managing this cancer type.

Who may be eligible for this renal cell carcinoma clinical trial?

Adults aged 18 to 90 years with locally advanced or advanced renal cell carcinoma who have suspicious metastases on contrast-enhanced CT may be eligible. Participants must be able to undergo PET/CT imaging and have no known venous problems. Please review eligibility criteria for more details.

Is there any cost to participate in this renal cell carcinoma clinical trial?

Study-related care, including the 68Ga-PSMA PET scan, enhanced CT, and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel or accommodation costs.

Actively Recruiting

Phase Not Applicable

Age: 18Years - 90Years

All Genders

ID04987086

Study of 68Ga-PSMA PET Scan Accuracy and Impact on Treatment in Advanced Renal Cell Carcinoma

Led by Xijing Hospital · Updated on 2026-03-11

300

Participants Needed

Research Sites

52 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating the diagnostic effectiveness of 68Ga-PSMA PET scans compared to enhanced CT scans in detecting metastatic lesions in patients with locally advanced and advanced renal cell carcinoma. The study also aims to see if 68Ga-PSMA PET can influence treatment decisions for these patients. This prospective, multicenter trial is sponsored by Xijing Hospital and focuses on improving diagnosis and management for renal cancer with metastases. Participants in the study will receive both a 68Ga-PSMA PET scan and an enhanced CT scan simultaneously to compare their abilities to detect cancer spread. This diagnostic approach helps assess the additional value that 68Ga-PSMA PET may provide over standard CT imaging. The study does not involve any masking or placebo groups and includes only patients who meet specific clinical and imaging criteria. During the study, patients will undergo imaging within six weeks after diagnosis, and researchers will track how the 68Ga-PSMA PET results affect treatment choices. The primary measurement is the additional diagnostic value of the PSMA PET compared to CT over two years. Secondary outcomes include how often the PET scan changes treatment decisions. The study monitors patient safety and adherence, with a planned follow-up period to evaluate outcomes until December 2027.

CONDITIONS

Brief Title

68Ga-PSMA PET in the Renal Cell Carcinoma

Who Can Participate

Age: 18Years - 90Years

All Genders

Eligibility Criteria

You may qualify if you...

Adults with 2017 AJCC renal cell carcinoma stage III or IV
Suspicious metastases found on contrast-enhanced CT staging
No known peripheral or central venous problems
Able to undergo 68Ga PSMA PET/CT imaging within 6 weeks after diagnosis
Signed informed consent for voluntary participation

You will not qualify if you...

Age 18 years or younger
Unable to lie flat for PET/CT examination
Contraindications for 68Ga PSMA ligands
History of other malignant tumors in past 2 years or complications affecting test
Impaired renal function or currently on hemodialysis

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here